Clinical trial
Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic…
NCT00108875 · Julius-Maximilians University, Other · Unknown status
Key facts
| NCT number | NCT00108875 |
|---|---|
| Title | Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer |
| Official title | Vaccination of Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer With HLA-A1, -A2 and -B35 Restricted Survivin Peptides |
| Lead sponsor | Julius-Maximilians University, Other |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma, Pancreatic Cancer, Colon Cancer, Cervical Cancer |
| Intervention type | Biological |
| Interventions | Survivin peptide vaccine |
| Enrollment | 70 |
| Start date | Apr 1, 2003 |
| First posted | Apr 20, 2005 |
| Last update posted | Jul 28, 2006 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: